Clinical Trials Sponsored by Chipscreen Biosciences, Ltd.

Total 361 results

Chipscreen Biosciences, Ltd.

Recruiting

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

Non Small Cell Lung Cancer

China
Chipscreen Biosciences, Ltd.

Recruiting

Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

China
Chipscreen Biosciences, Ltd.

Recruiting

Mass Balance Study of [14C]Chiauranib

Small Cell Lung Cancer

China
Chipscreen Biosciences, Ltd.

Recruiting

Chiglitazar Added to Metformin for Type 2 Diabetes

Type 2 Diabetes

China
Chipscreen Biosciences, Ltd.

Completed

A Clinical Trial of CS12192 in Healthy Subjects

Healthy

China
Chipscreen Biosciences, Ltd.

Completed

Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients (CMAS)

Type 2 Diabetes

China
Chipscreen Biosciences, Ltd.

Terminated

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

China
Chipscreen Biosciences, Ltd.

Not yet recruiting

A Study of NWY001 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Chipscreen Biosciences, Ltd.

Recruiting

Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function

Renal Impairment

China
Chipscreen Biosciences, Ltd.

Recruiting

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

Soft Tissue Sarcoma

China
Chipscreen Biosciences, Ltd.

Recruiting

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Triple-negative Breast Cancer

China
Chipscreen Biosciences, Ltd.

Active, not recruiting

Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL (DEB)

Diffuse Large B-cell Lymphoma

China
Chipscreen Biosciences, Ltd.

Completed

Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer

Small Cell Lung Cancer

China
Chipscreen Biosciences, Ltd.

Active, not recruiting

Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Non Small Cell Lung Cancer

China
Chipscreen Biosciences, Ltd.

Completed

Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Breast Cancer

China
Chipscreen Biosciences, Ltd.

Completed

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

Ovarian Cancer

China
Chipscreen Biosciences, Ltd.

Completed

Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients (CMAP)

Type 2 Diabetes

China
Chipscreen Biosciences, Ltd.

Completed

Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients

Peripheral T-cell Lymphoma

China
Chipscreen Biosciences, Ltd.

Completed

Phase I Study of Chiauranib in Patients With Advanced Solid Tumors

Solid Tumors

China
Chipscreen Biosciences, Ltd.

Completed

Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer

Non-small-cell Lung Cancer

China
Chipscreen Biosciences, Ltd.

Recruiting

A Study of CS23546 in Subjects With Advanced Tumors

Advanced Tumors

China
Chipscreen Biosciences, Ltd.

Not yet recruiting

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules

Healthy

China
Chipscreen Biosciences, Ltd.

Recruiting

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. (SCLC)

Small Cell Lung Cancer | Advanced Solid Malignant Tumor

United States
Chipscreen Biosciences, Ltd.

Recruiting

A Phase II Clinical Trial of Chiglitazar for NASH

NASH

China
Chipscreen Biosciences, Ltd.

Recruiting

Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer (CHIPRO)

Ovarian Cancer | Relapsed or Refractory | Chiauranib | Paclitaxel

China
Chipscreen Biosciences, Ltd.

Recruiting

Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer

Small Cell Lung Cancer

China
Chipscreen Biosciences, Ltd.

Completed

Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

T2DM

China
Chipscreen Biosciences, Ltd.

Completed

Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Non-hodgkin's Lymphoma

China
Chipscreen Biosciences, Ltd.

Completed

Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Chipscreen Biosciences, Ltd.

Completed

Phase Ib Study of Chiauranib in Patients With Ovarian Cancer

Ovarian Cancer

China
Akeso
Chipscreen Biosciences, Ltd.

Recruiting

A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer

SCLC,Extensive Stage

Australia, China
Tang-Du Hospital
Chipscreen Biosciences, Ltd.

Completed

Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir (CHARTER)

Chronic HIV Infections

China
Sun Yat-sen University
Chipscreen Biosciences, Ltd.

Not yet recruiting

Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR) (PCR)

Relapsed or Refractory DLBCL
Peng Liu
Chipscreen Biosciences, Ltd.

Unknown

Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM

Multiple Myeloma

China
Chipscreen Biosciences, Ltd.
H & J CRO International, Inc.

Completed

Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers

Healthy Volunteers

China
Guangdong Provincial People's Hospital
Shenzhen Chipscreen Biosciences Co.Ltd

Recruiting

A Study of Chidamide With AZA in MRD Positive AML After Transplant

Minimal Residual Disease | AML, Adult

China
Anwita Biosciences
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 1 First-in-human Study of JS014

Lymphoma | Solid Tumor, Adult | Neoplasm Malignant | Neoplasm, Experimental

Taiwan
Shanghai Junshi Bioscience Co., Ltd.
Iqvia Pty Ltd; TopAlliance Biosciences, Inc.

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

Advanced Malignancies

United States
Clexio Biosciences Ltd.

Recruiting

A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder (SOLEO)

Adjunctive Treatment of Major Depressive Disorder (MDD)

United States
Liminal BioSciences Ltd.

Terminated

A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate

Hyperammonemia

United Kingdom
Liminal BioSciences Ltd.

Terminated

Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome

Type 2 Diabetes Mellitus | Metabolic Syndrome

Canada
Liminal BioSciences Ltd.

Completed

A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis (IPF)

Canada
Prothena Biosciences Ltd.

Terminated

Study in Subjects With Light Chain (AL) Amyloidosis

AL Amyloidosis

United States, Spain, Australia, Italy, Germany, Austria, Greece, France, Israel, United Kingdom
Clasado Biosciences Ltd

Withdrawn

Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea

Traveler's Diarrhea
Coherus Biosciences, Inc.
Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.

Active, not recruiting

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States
Modern Biosciences Ltd

Not yet recruiting

Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects

Pharmacokinetics

United Kingdom
Prothena Biosciences Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis (AFFIRM-AL)

Light Chain (AL) Amyloidosis

United States, Korea, Republic of, Australia, Denmark, France, Italy, Spain, Israel, Taiwan, Austria, Canada, Czechia, Germany, Greece, Hungary, Japan, Netherlands, Poland, Portugal, Turkey, United Kingdom, Belgium, Ireland
Modern Biosciences Ltd

Completed

Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA

Rheumatoid Arthritis

Bosnia and Herzegovina, Bulgaria, Chile, Czechia, Guatemala, Mexico, Poland, Serbia
Clexio Biosciences Ltd.

Completed

A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

Adjunctive Treatment of Major Depressive Disorder

United States, Puerto Rico
Liminal BioSciences Ltd.

Completed

A Healthy Volunteer Study of PBI-4050

Fibrosis | Inflammation

United Kingdom

Clinical Trials Sponsored by Chipscreen Biosciences, Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations